Biosimilars have the potential to lower costs. But due to middlemen like pharmacy benefit managers (PBMs), those savings don’t always trickle down to patients at the pharmacy counter. How can we fix this system?

Julie Reed, executive director of the Biosimilars Forum, joins the podcast to explain what biosimilars are, why uptake has been slow, and what can be done to improve patient access and lower costs. 

We also hear from Lauren Kopsick, who shares her experience navigating burdensome step therapy requirements for her son’s care. 

>> LISTEN HERE